| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10967395 | Vaccine | 2013 | 7 Pages |
Abstract
A single dose of RV3-BB rotavirus vaccine was well tolerated in adults, children and infants. Most infants (8/9) who received RV3-BB demonstrated vaccine take following a single dose. These data support progression of RV3-BB to Phase II immunogenicity and efficacy trials.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
M. Danchin, C.D. Kirkwood, K.J. Lee, R.F. Bishop, E. Watts, F.A. Justice, V. Clifford, D. Cowley, J.P. Buttery, J.E. Bines,